| Document |
Document Title |
|
WO/1984/001149A1 |
A novel polypeptide represented by the following formula: H-Lys-Arg-Lys-Arg-Ser-Gln-Met-Leu-Phe-Arg-Gly-Arg-Arg-Ala-Se
r-Gln-OH and a conjugated protein thereof, hybridoma and monoclonal antibody induced from said polypeptide or said con...
|
|
WO/1984/000540A1 |
A polypeptide having the cell-attaching activity of fibronectin. The polypeptide has 180 amino acid residues and the formula:$(15,)$The polypeptide or a biologically active fragment thereof, such as$(6,)$can be employed in the preparatio...
|
|
WO/1983/002114A1 |
A method of preparing highly purity procoagulant protein comprising the steps of (a) adsorbing a VIII:C/VIII:RP complex from a plasma or commercial concentrate source of factor VIII onto agarose beads bound to a monoclonal antibody speci...
|
|
WO/1979/000609A1 |
When coupling protein and non-protein affinity ligands to solid-phase supports activated with trichloro-s-triazine (TsT), the TsT activated solid-phase support is prepared by reacting a water-free insoluble solid support with TsT in a no...
|
|
JP7490735B2 |
Disclosed is a general, reversible bicyclization strategy to increase both the proteolytic stability and cell permeability of peptidyl drugs. A peptide drug is fused with a short cell-penetrating motif and converted into a conformational...
|
|
JP2024520756A |
Provided herein is a pharmaceutical composition comprising a lipid nanoparticle (LNP) and a therapeutic nucleic acid (TNA), wherein the LNP comprises an ApoE polypeptide, or a fragment thereof, and/or an ApoB polypeptide, or a fragment t...
|
|
JP2024069260A |
Therapeutic antibodies capable of binding glycans, including glycans associated with disease and abnormal cells and tissues, as well as methods of using such antibodies and targeting abnormal cells and tissues. Provide a better way to de...
|
|
JP2024069247A |
The present invention provides a minimally engineered G protein alpha that is capable of binding to a GPCR and inducing the core pharmacological and conformational changes associated with the high affinity agonist-bound state. [Solution]...
|
|
JP2024516907A |
The present invention relates primarily to protein purification in the field of chromatography. More particularly, the present invention relates to affinity chromatography using a split intein system comprising a C-intein tag and an N-in...
|
|
JP2024516548A |
The present disclosure provides a method of identifying a human subject at risk of developing progressive renal function decline by examining the level(s) of protective protein(s) in a sample from the subject. Level(s) of protein(s) iden...
|
|
JP7465900B2 |
Reagents for use in sandwich immunoassays for haptens are disclosed, along with kits containing same. Also disclosed are diagnostic immunoassay methods that utilize these immunoassay reagents in a particle enhanced agglutination detectio...
|
|
JP2024515676A |
The present disclosure provides, among other things, methods and compositions for oral administration of polypeptides. Typically, many polypeptides are administered in solution by intravenous or subcutaneous injection. The present disclo...
|
|
JP2024515306A |
Bicyclic peptide ligand specific for P-selectin The present invention relates to polypeptides that are covalently attached to a molecular scaffold such that two or more peptide loops reside between the points of attachment to the molecul...
|
|
JP2024045268A |
The present invention provides novel monoclonal antibodies that, when used in standard immunoassay methods, enable reliable detection and quantification of hTK-1 from body fluid samples. The present invention provides a novel monoclonal ...
|
|
JP2024513126A |
The present invention relates to a polypeptide forming one part of a two-part linker, wherein the polypeptide forms an isoisomer in the two-part linker with a peptide tag that is the second part of the two-part linker. Relates to polypep...
|
|
JP2024037552A |
[Problem] To provide a highly versatile method for producing a hydrogel-embedded protein crystal that can be applied to any protein as long as it can be crystallized. [Solution] Inside an extrudable shape containing an acrylamide solutio...
|
|
JP2024512741A |
The present disclosure generally relates to binding agents that have the ability to target tumor cells and/or immune cells. The binding agents of the present disclosure include one or more antigen-binding domains of a heavy chain antibod...
|
|
JP7452836B2 |
To provide a method for making hydrogel-embedded protein crystal with rich versatility.A solution including crystallized protein within an article in the shape allowing extrusion with liquid, is extruded with one of an alginic acid solut...
|
|
JP2024510426A |
The present invention provides a method for providing a cargo to the C-terminus (111) of the peptide (110), comprising a first step and a second step, the first step being the C-terminus (111) of the peptide (110). reacting the terminal ...
|
|
JP2024028816A |
A method is needed to detect early stage kidney disease so that disease progression can be halted. Kind Code: A1 A creatinine assay can detect grade 1, 2, or 3 acute kidney injury (AKI) in a human before it can detect grade 1, 2, or 3 ac...
|
|
JP2024509822A |
The present disclosure relates to molecular barcodes that include a set of one or more identimers. A method of using the molecular barcode, eg, to classify materials, is disclosed. Disclosed herein are methods of making the molecular bar...
|
|
JP2024509924A |
Provided herein are affinity agents that include a ligand that specifically binds to a target molecule. Compatibility agents are useful for binding, isolation, and/or purification. [Selection diagram] Figure 1
|
|
JP2024026911A |
The present invention provides insoluble particles that exhibit excellent aggregation ability when an antigen-antibody reaction occurs. [Solution] Insoluble particles contain a particulate carrier such as latex particles, and an antibody...
|
|
JP7441209B2 |
The objective of the present invention is to provide a method for efficiently supporting a thiol group-including compound on an insoluble base material. The method for supporting a thiol group-including compound on an insoluble base mate...
|
|
JP2024508832A |
Spherical nucleic acids (SNAs) are attractive platforms for therapeutic delivery due to their chemically tunable structure, biocompatibility, and ability to rapidly enter cells without transfection reagents. The present disclosure provid...
|
|
JP2024024658A |
[Problem] To provide a ligand protein for an immunoglobulin adsorbent that allows antibody elution under milder conditions than conventional immunoglobulin adsorbents. [Solution] Contains the amino acid sequence of the immunoglobulin bin...
|
|
JP7434248B2 |
Several embodiments of the present disclosure relate to therapeutic compositions configured to target the liver of a subject and that are useful in the treatment or prevention of one or more of transplant rejection, autoimmune disease, f...
|
|
JP7434358B2 |
Provide are a porous cell scaffold including a serum-induced protein and a method of manufacturing the same. A porous cell scaffold according to an embodiment may stably and continuously incubate cells, show a culture pattern suitable fo...
|
|
JP2024505438A |
The present disclosure provides, in some aspects, antigen-specific amino acid sequences for tick-borne Borrelia relapsing species. [Selection diagram] Figure 1
|
|
JP7425946B2 |
To provide a protein, cell or microorganism adhesion inhibitor exhibiting excellent adhesion inhibitory force against proteins, cells or microorganisms, and a blocking agent for biochemical analysis containing the adhesion inhibitor, bio...
|
|
JP2024012350A |
The present invention provides improved hydrogel scaffolds comprising conjugates of synthetic polymers and extracellular matrix proteins. A non-crosslinked, stable, ready-to-use liquid composition comprising a protein-polymer conjugate a...
|
|
JP7423684B2 |
The present invention relates to artificial antigen presenting cell (aAPC) scaffolds to provide cells with specific functional stimulation to obtain phenotypic and functional properties ideal to mediate tumor regression or viral clearanc...
|
|
JP2024009472A |
[Problem] The present invention clarifies the true cause of interstitial pneumonia accompanying myositis/dermatomyositis, and increases the risk of developing interstitial pneumonia accompanying myositis/dermatomyositis or rapidly progre...
|
|
JP7419217B2 |
A method for selecting a G-protein coupled receptor (GPCR) with increased stability, the method comprising(a) providing one or more mutants of a parent GPCR,(b) selecting a ligand, the ligand being one which binds to the parent GPCR when...
|
|
JP7416384B2 |
A method in which a solution that includes an amphipathic molecule and protein is used to coat gold particles.
|
|
JP7416383B2 |
A method in which gold particles are coated with protein, the method being characterized by using either of the following buffering solutions. 1) A buffering solution that has a final salt concentration, excluding MgCl2 and DTT, of great...
|
|
JP7416715B2 |
There is provided a method for producing a peptide-nucleic acid complex containing a peptide and a nucleic acid encoding the peptide. The method for producing a peptide-nucleic acid complex includes a step of preparing a nucleic acid to ...
|
|
JP7414106B2 |
To provide a ligand protein of immunoglobulin adsorbent which enables antibody elution in milder conditions than those in the conventional immunoglobulin adsorbents.The present invention solves the above problem by including an amino aci...
|
|
JP2023183863A |
To provide a method for efficient concentration of SARS-CoV-2 and a kit therefor.A method for concentration of SARS-CoV-2 according to the present invention is designed to concentrate SARS-CoV-2 in a sample. The method includes the steps...
|
|
JP7404689B2 |
To provide antibody-adsorbing agents obtainable by immobilizing an affinity ligand capable of specifically binding to antibodies onto an insoluble carrier, which can adsorb a large amount of antibodies so that the agents are usable for a...
|
|
JP2023553038A |
The present invention relates to a method of producing nanoparticles, the step of: (c) contacting an antibody with a composition comprising a first conjugate (A), wherein the first conjugate is a bifunctional linker. a positively charged...
|
|
JP2023179759A |
To provide a novel method of synthesizing peptides.The present invention discloses high-purity peptides and peptaibols obtained by solid-phase peptide synthesis using, as a starting resin, a polymer having hydroxyamino acid, hydroxyamino...
|
|
JP2023178881A |
To provide an anti-MSP antibody that exhibits high affinity for MSP constituting nanodiscs, or an antigen-binding fragment thereof.The present invention provides a monoclonal antibody for a membrane scaffold protein (MSP) or an antigen-b...
|
|
JP2023178884A |
To provide a high-affinity monoclonal antibody for a His-tag added to the C terminus of membrane protein.The present invention provides a monoclonal antibody for a histidine tag (His-tag) or an antigen-binding fragment thereof, wherein t...
|
|
JP2023552375A |
Methods are provided for reducing and/or preventing interference in a serological assay with a drug comprising (i) an antibody Fc region and (ii) a moiety that binds human CD47. [Selection diagram] None
|
|
JP7383249B2 |
The present invention provides a method for quantitatively detecting β-1,3-1,6-glucan separately from β-1,3-glucan and β-1,3-1,4-glucan. The present invention is a method for measuring β-1,3-1,6-glucan, the method including: a step f...
|
|
JP2023164915A |
To provide a histogenesis-inducing compound, a biomaterial including the compound, and medical equipment.Provided is a cyclic peptide that has 15 to 35 amino acids and can bind to a growth factor receptor, or a variant or an analogue the...
|
|
JP7373993B2 |
Various aspects of the invention relate to recombinant polypeptides that specifically bind human von Willebrand Factor. Such recombinant polypeptides typically include a modified extracellular domain of platelet glycoprotein Ibα that ty...
|
|
JP7370538B2 |
An object of the present invention is to provide a separating agent with an improved dynamic binding capacity (DBC) to a target substance and the object is achieved with a separating agent including a carrier and a protein, wherein the p...
|
|
JP7371019B2 |
The present disclosure relates generally to methods for the prognosis and management of amyotrophic lateral sclerosis (ALS), as well as associated compositions, kits, solid supports and uses.
|
